{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:59:35Z","timestamp":1790531975076,"version":"4.1.0"},"reference-count":42,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.3960\/jslrt.18034","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T17:27:42Z","timestamp":1544635662000},"page":"152-160","source":"Crossref","is-referenced-by-count":19,"title":["Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia\/lymphoma"],"prefix":"10.3960","volume":"58","author":[{"given":"Yoshihiro","family":"Komohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Noyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Takeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Baghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichiro","family":"Seino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Suzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol. 1991; 79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Katsuya H, Ishitsuka K, Utsunomiya A <i>et al.<\/i>. Treatment and survival among 1594 patients with ATL. Blood. 2015; 126: 2570-2577.","DOI":"10.1182\/blood-2015-03-632489"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Murata K, Yamada Y. The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL. Int Rev Immunol. 2007; 26: 249-268.","DOI":"10.1080\/08830180701709817"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012; 119: 1810-1820.","DOI":"10.1182\/blood-2011-09-379214"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Baghdadi M, Umeyama Y, Hama N <i>et al.<\/i> Interleukin-34, a comprehensive review. J Leukoc Biol. 2018; 104: 931-951.","DOI":"10.1002\/JLB.MR1117-457R"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lin H, Lee E, Hestir K <i>et al.<\/i> Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008; 320: 807-811.","DOI":"10.1126\/science.1154370"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Rahmati M, Petitbarat M, Dubanchet S <i>et al.<\/i> Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. J Reprod Immunol. 2015; 109: 1-6.","DOI":"10.1016\/j.jri.2015.01.005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kascinski B. Expression of CSF-1 and its receptor CSF-1R in non-hematopoietic neoplasms. Cancer Treat Res. 2002; 107: 285-292.","DOI":"10.1007\/978-1-4757-3587-1_13"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ries CH, Hoves S, Cannarile MA, R\u00fcttinger D. CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol. 2015; 23: 45-51.","DOI":"10.1016\/j.coph.2015.05.008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol. 2014; 5: 489.","DOI":"10.3389\/fimmu.2014.00489"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Mills K. Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Front Biosci. 2008; Volume: 4605-4616.","DOI":"10.2741\/3026"},{"key":"12","unstructured":"12 Gruss HJ, Brach MA, Drexler HG <i>et al.<\/i> Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 1992; 52: 3353-3360."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nosaka K, Miyamoto T, Sakai T <i>et al.<\/i> Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells. Blood. 2002; 99: 634-640.","DOI":"10.1182\/blood.V99.2.634"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 El-Gamal MI, Anbar HS, Yoo KH, Oh CH. FMS Kinase Inhibitors: Current Status and Future Prospects. Med Res Rev. 2013; 33: 599-636.","DOI":"10.1002\/med.21258"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Burns CJ, Wilks AF. c-FMS inhibitors: a patent review. Expert Opin Ther Pat. 2011;21:147-165.","DOI":"10.1517\/13543776.2011.545348"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Butowski N, Colman H, De Groot JF <i>et al.<\/i> Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncol. 2016; 18: 557-564.","DOI":"10.1093\/neuonc\/nov245"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 DeNardo DG, Brennan DJ, Rexhepaj E <i>et al.<\/i> Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1: 54-67.","DOI":"10.1158\/2159-8274.CD-10-0028"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Dammeijer F, Lievense LA, Kaijen-Lambers ME <i>et al.<\/i> Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunol Res. 2017; 5: 535-546.","DOI":"10.1158\/2326-6066.CIR-16-0309"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Stafford JH, Hirai T, Deng L <i>et al.<\/i> Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro-oncol. 2016; 18: 797-806.","DOI":"10.1093\/neuonc\/nov272"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Nakagawa T, Ohnishi K, Kosaki Y <i>et al.<\/i> Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop. 2017; 57: 31-36.","DOI":"10.3960\/jslrt.17017"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Baghdadi M, Endo H, Takano A <i>et al.<\/i> High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep. 2018; 8: 418.","DOI":"10.1038\/s41598-017-18796-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy. Oncogene. 2005; 24: 6047-6057.","DOI":"10.1038\/sj.onc.1208979"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Chihara T, Suzu S, Hassan R <i>et al.<\/i> IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010; 17: 1917-1927.","DOI":"10.1038\/cdd.2010.60"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Hide T, Komohara Y, Miyasato Y <i>et al.<\/i> Oligodendrocyte Progenitor Cells and Macrophages\/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. EBioMedicine. 2018; 30: 94-104.","DOI":"10.1016\/j.ebiom.2018.02.024"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Takaishi K, Komohara Y, Tashiro H <i>et al.<\/i> Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010; 101: 2128-2136.","DOI":"10.1111\/j.1349-7006.2010.01652.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci. 2011; 102: 206-211.","DOI":"10.1111\/j.1349-7006.2010.01772.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Horlad H, Ma C, Yano H <i>et al.<\/i> An IL-27\/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1\/2) on infiltrating macrophages in lymphoma. Cancer Sci. 2016; 107: 1696-1704.","DOI":"10.1111\/cas.13065"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Lau J, Cheung J, Navarro A <i>et al.<\/i> Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017; 8: 14572.","DOI":"10.1038\/ncomms14572"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Katsuya H, Ishitsuka K. Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. J Clin Exp Hematop. 2017; 57: 87-97.","DOI":"10.3960\/jslrt.17008"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Komohara Y, Niino D, Saito Y <i>et al.<\/i> Clinical significance of CD163 + tumor-associated macrophages in patients with adult T-cell leukemia\/lymphoma. Cancer Sci. 2013; 104: 945-951.","DOI":"10.1111\/cas.12167"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Horlad H, Ohnishi K, Ma C <i>et al.<\/i> TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia\/lymphoma. Oncol Lett. 2016; 12: 1519-1524.","DOI":"10.3892\/ol.2016.4774"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Lin H, Lee E, Hestir K <i>et al.<\/i> Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008; 320: 807-811.","DOI":"10.1126\/science.1154370"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Zhou RP, Wu XS, Xie YY <i>et al.<\/i> Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology. 2016; 149: 362-373.","DOI":"10.1111\/imm.12660"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35 Chang EJ, Lee SK, Song YS <i>et al.<\/i> IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab. 2014; 99: E1263-E1271.","DOI":"10.1210\/jc.2013-4409"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36 S\u00e9galiny AI, Mohamadi A, Dizier B <i>et al.<\/i> Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015; 137: 73-85.","DOI":"10.1002\/ijc.29376"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37 Zins K, Heller G, Mayerhofer M, Schreiber M, Abraham D. Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes. Oncotarget. 2018; 9: 23126-23148.","DOI":"10.18632\/oncotarget.25226"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38 Franz\u00e8 E, Dinallo V, Rizzo A <i>et al.<\/i> Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue. Oncotarget. 2017; 9: 3432-3445.","DOI":"10.18632\/oncotarget.23289"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39 Giricz O, Mo Y, Dahlman KB <i>et al.<\/i> The RUNX1\/IL-34\/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018; 3: e120422; Epub ahead of print.","DOI":"10.1172\/jci.insight.120422"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40 Ansell SM, Lesokhin AM, Borrello I <i>et al.<\/i> PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 372: 311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41 Miyoshi H, Kiyasu J, Kato T <i>et al.<\/i> PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood. 2016; 128: 1374-1381.","DOI":"10.1182\/blood-2016-02-698936"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42 Ma C, Horlad H, Pan C <i>et al.<\/i> Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. J Clin Exp Hematop. 2017; 57: 21-25.","DOI":"10.3960\/jslrt.17006"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43 Kataoka K, Shiraishi Y, Takeda Y <i>et al.<\/i> Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature. 2016; 534: 402-406.","DOI":"10.1038\/nature18294"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/58\/4\/58_18034\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T07:38:35Z","timestamp":1605598715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/58\/4\/58_18034\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.18034","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}